QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Anacor Pharmaceuticals Inc. (ANAC) and Medicis Pharmaceutical Corp. (MRX) Ink Collaboration Agreement 0 comments
    Feb 10, 2011 1:52 PM | about stocks: ANAC

    Anacor Pharmaceuticals Inc. and Medicis Pharmaceutical Corp. today announced they have entered into a research and development agreement to discover and develop boron-based small molecule compounds directed against a target for the patented, potential treatment of acne.

    “We are pleased to announce this important collaboration with Anacor,” Jonah Shacknai, chairman and CEO of Medicis stated in the press release. “Anacor and its scientists are well respected in the scientific community, and Medicis is proud to be among other significant organizations who have partnered with them to explore the pharmaceutical development of the Anacor boron chemistry platform. We will together be working hard to achieve breakthroughs with this proprietary technology in the treatment of acne.”

    The agreement calls for Anacor to receive an upfront payment of $7 million from Medicis. Anacor will be eligible for future research, development, regulatory and sales milestones of up to $153 million, as well as high single-digit to low double-digit royalties on sales by Medicis.

    Anacor will be primarily responsible for discovering and conducting early development of product candidates utilizing Anacor’s proprietary boron chemistry platform, while Medicis will be responsible for further development and commercialization of the licensed products on a worldwide basis.

    Per the agreement, Medicis will have an option to obtain an exclusive license for products covered by the agreement.

    Anacor CEO David Perry noted the potential of the collaboration of the two companies’ resources.

    “We have demonstrated that boron-based chemistry is productive in creating novel small molecule therapeutics, and we are excited to work with Medicis to apply this technology to the development of a unique, patented treatment for acne,” Perry stated. “With our technology and Medicis’ expertise in developing and commercializing pharmaceuticals, we hope this collaboration will result in innovative products to help the patients who suffer from this condition.”

    For more information visit anacor.com or medicis.com

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ANAC
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.